ARTICLE | Company News
GCOR, SGEN cancer prodrug deal
January 7, 2002 8:00 AM UTC
Genencor (GCOR) and Seattle Genetics (SGEN) partnered to develop cancer therapeutics. The deal combines SGEN's antibody-directed enzyme prodrug therapy (ADEPT) technology with GCOR's targeted enzyme p...